Literature DB >> 20201861

Regulator of G protein-signaling proteins and addictive drugs.

John Traynor1.   

Abstract

Regulator of G protein-signaling (RGS) proteins are a family of more than 30 intracellular proteins that negatively modulate intracellular signaling of receptors in the G protein-coupled receptor family. This family includes receptors for opioids, cannabinoids, and dopamine that mediate the acute effects of addictive drugs or behaviors and chronic effects leading to the development of addictive disease. Members of the RGS protein family, by negatively modulating receptor signaling, influence the intracellular processes that lead to addiction. In turn, addictive drugs control the expression levels of several RGS proteins. This review will consider the distribution and mechanisms of action of RGS proteins, particularly the R4 and R7 families that have been implicated in the actions of addictive drugs, how knowledge of these proteins is contributing to an understanding of addictive processes, and whether specific RGS proteins could provide targets for the development of medications to manage and/or treat addiction.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20201861     DOI: 10.1111/j.1749-6632.2009.05150.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  19 in total

Review 1.  A finer tuning of G-protein signaling through regulated control of RGS proteins.

Authors:  Jacob Kach; Nan Sethakorn; Nickolai O Dulin
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-04-27       Impact factor: 4.733

2.  β-arrestin2 plays permissive roles in the inhibitory activities of RGS9-2 on G protein-coupled receptors by maintaining RGS9-2 in the open conformation.

Authors:  Mei Zheng; Sang-Yoon Cheong; Chengchun Min; Mingli Jin; Dong-Im Cho; Kyeong-Man Kim
Journal:  Mol Cell Biol       Date:  2011-10-17       Impact factor: 4.272

3.  Gi/o-coupled receptors compete for signaling to adenylyl cyclase in SH-SY5Y cells and reduce opioid-mediated cAMP overshoot.

Authors:  Erica S Levitt; Lauren C Purington; John R Traynor
Journal:  Mol Pharmacol       Date:  2010-11-22       Impact factor: 4.436

Review 4.  Dopamine D2 autoreceptor interactome: Targeting the receptor complex as a strategy for treatment of substance use disorder.

Authors:  Rong Chen; Mark J Ferris; Shiyu Wang
Journal:  Pharmacol Ther       Date:  2020-05-27       Impact factor: 12.310

Review 5.  Regulators of G-protein signaling and their Gα substrates: promises and challenges in their use as drug discovery targets.

Authors:  Adam J Kimple; Dustin E Bosch; Patrick M Giguère; David P Siderovski
Journal:  Pharmacol Rev       Date:  2011-07-07       Impact factor: 25.468

Review 6.  Current approaches for the discovery of drugs that deter substance and drug abuse.

Authors:  Adam Yasgar; Anton Simeonov
Journal:  Expert Opin Drug Discov       Date:  2014-09-24       Impact factor: 6.098

Review 7.  μ-Opioid receptors and regulators of G protein signaling (RGS) proteins: from a symposium on new concepts in mu-opioid pharmacology.

Authors:  John Traynor
Journal:  Drug Alcohol Depend       Date:  2011-11-29       Impact factor: 4.492

Review 8.  Activators of G-protein signaling 3: a drug addiction molecular gateway.

Authors:  Michael Scott Bowers
Journal:  Behav Pharmacol       Date:  2010-09       Impact factor: 2.293

9.  The brain gene expression profile of dopamine D2/D3 receptors and associated signaling proteins following amphetamine self-administration.

Authors:  H Sun; E S Calipari; T J R Beveridge; S R Jones; R Chen
Journal:  Neuroscience       Date:  2015-08-28       Impact factor: 3.590

Review 10.  RNA-binding proteins, neural development and the addictions.

Authors:  C D Bryant; N Yazdani
Journal:  Genes Brain Behav       Date:  2016-01       Impact factor: 3.449

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.